



Australian Technical Advisory Group on Immunisation (ATAGI)

Summary of the 118th meeting, 17 December 2025

Respiratory syncytial virus (RSV)

- ATAGI reviewed the draft GRADE evidence to decision framework for clesrovimab, a monoclonal antibody to protect infants against RSV, which is currently under evaluation by the Therapeutic Goods Administration (TGA).
- [ATAGI's recommendations for RSV prevention](#) are on the Australian Immunisation Handbook website.

Influenza

- ATAGI reviewed data on a second annual influenza dose for older adults and found insufficient evidence to change current recommendations. ATAGI noted the Australian Health Protection Committee had published a [statement on influenza activity and guidance for the holiday season](#).
- ATAGI reviewed the GRADE assessment and evidence to decision framework for the use of Fluad influenza vaccine in adults aged 50 to 64 years.
- ATAGI reviewed the draft 2026 influenza statement and updated Handbook chapter, which will be published late February 2026 and early March 2026 respectively.

Barriers to vaccination

- ATAGI received a presentation on preliminary data from the [National Vaccination Insights Project](#) for 2025. The project involves serial surveys of adults about influenza vaccine, and of parents of children aged ≤5 years about childhood vaccines, to identify barriers to vaccination and inform strategies to improve uptake in Australia.
- Potential strategies and policy considerations to improve uptake resulting from the 2024 survey have been published in the [Australian and New Zealand Journal of Public Health](#).

COVID-19

- ATAGI reviewed additional information to be provided to the National Health and Medical Research Council (NHMRC) as part of NHMRC's consideration of the COVID-19 chapter of the Handbook at the upcoming NHMRC Council meeting in the first week of April.

Other ATAGI business

- ATAGI received an update from the TGA Advisory Committee on Vaccines on preparation errors relating to [Infanrix hexa \(DTPa-HepB-IPV-Hib\) vaccine](#). ATAGI emphasises to providers that this vaccine must be reconstituted by adding the contents of the pre-filled syringe to the lyophilised pellet in the vial.
- ATAGI noted a summary of highlights from the 6th Global NITAG Network (GNN) meeting held in November in Morocco.

Resources

- ATAGI's membership, terms of reference and declaration of interest information is available on the [Department of Health, Disability and Ageing website](#).